John McEnroe is on the call of the men's championship match at Wimbledon on Sunday. The iconic American tennis player, who ...

From polyaphron technology to fixed combinations, new formulations improve tolerability, adherence, and patient satisfaction. Join Drs Feldman and Armstrong as they discuss.

One of the more serious side effects from immune checkpoint inhibitor (ICI) therapies for cancer is new-onset or worsened ...

A new trial finds guselkumab is highly effective and well tolerated for moderate to severe scalp psoriasis in individuals ...

A large cohort study of patients with psoriasis using wearable devices finds more exercise is associated with a lower risk ...

Guselkumab and risankizumab for psoriasis have the highest rates of drug survival among biologics measured and a comparable safety profile.

Some medicines used for heart problems, like beta-blockers, ACE inhibitors, and calcium channel blockers, have been known to ...

Promising Psoriasis Pipeline Therapies such as Hypericin, EDP1815, Cetaphil, AX-158, HAT1 topical solution, Calcipotriol, ARQ ...

A global comparison of psoriatic arthritis guidelines reveals differences in treatment sequencing and domain-specific strategies, with all emphasizing treat-to-target goals and comorbidity management.

Boehringer Ingelheim, one of the industry leading investors in research and development in innovative life expectancy therapies, announced a $105 million (€90 million) global license and transfer ...

A new study published in the Journal of American Medical Association showed that Guselkumab was highly effective and durable ...

Incidences of malignant neoplasms were low and stable with long-term ixekizumab treatment for people with psoriatic disease ...